新闻
KMPH
--
0.00%
--
KemPharm 宣布在美国推出 Corium, Inc. 的创新 ADHD 治疗 AZSTARYS。
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for
Benzinga · 07/21 12:34
KemPharm 宣布在美国推出多动症治疗药物 AZSTARYS By Corium
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for
Benzinga · 07/21 12:32
KemPharm 在美国推出治疗多动症的 Azstarys
MT Newswires · 07/21 10:44
高达 3.5 亿美元的混合货架的 Brief-KemPharm 文件
reuters.com · 07/02 22:22
Brief-Kempharm Inc 通过出售股东申请持有 150 万股普通股
reuters.com · 06/25 21:02
认股权证交换后,KemPharm 股价下跌 12%
marketwatch.com · 06/18 16:52
周五盘中交易的12只医疗保健股
 
Benzinga · 06/18 16:45
KemPharm 行使现有认股权证,在私募中发行新认股权证;股价下跌
MT Newswires · 06/18 10:21
为什么这个消息可以帮助 KemPharm 股票突破:技术分析
KemPharm Inc. (NASDAQ: KMPH) shares moved higher Thursday after it was announced the company is being added to the Russell 3000 and Russell 2000 indexes based on the index provider's annual reconstitution.
Benzinga · 06/10 18:51
BRIEF-Kempharm To Be Added To Russell 2000® And Russell 3000® Indexes Effective June 28, 2021
reuters.com · 06/09 11:34
KemPharm 将加入罗素 3000、2000 指数;股价在响铃前上涨
MT Newswires · 06/09 09:38
KemPharm报告橙皮书列出了六种涵盖注意力缺陷障碍药物的专利
MT Newswires · 05/26 10:04
KemPharm Q1 EPS $(0.54)缺少$(0.17)估计,销售额$ 1,210万击败$ 210万估计
KemPharm (NASDAQ:KMPH) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.17) by 217.65 percent. This is a 350 percent decrease over losses of $(0.12) per share from the
Benzinga · 05/13 20:45
周四盘后交易中的12种医疗保健股
Gainers
Benzinga · 05/13 20:39
KemPharm Q1亏损缩小,销售激增
MT Newswires · 05/13 17:50
-Earning Flash(KMPH)KEMPHARM报告第一季度收入为1,210万美元
MT Newswires · 05/13 16:24
收益反应记录:KEMPHARM INC,追踪指标为66.7%,敏感值为6.2%
MT Newswires · 05/13 12:34
预计2021年5月13日的收入
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 05/13 08:15
KemPharm宣布DEA已将Serdexmethylphenidate(SDX)列为IV类受控物质
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that serdexmethylphenidate (SDX), KemPharm's proprietary prodrug of
Benzinga · 05/07 11:33
KemPharm:DEA将Serdexmethylphenidate归为附表IV受控物质;分享预铃
MT Newswires · 05/07 08:10
微牛提供丰富的实时KMPH股票新闻,让你可以通过多个平台了解KMPH股票行情最新动态,这些免费的KemPharm新闻可以帮助你做出明智投资。
KMPH 简况
KemPharm, Inc.是一家临床阶段的专业制药公司。该公司从事前体药物的发现与开发业务。该公司使用配体激活疗法(LAT)平台技术制备前体药物。该公司候选产品KP201/APAP由与醋氨酚(APAP)结合的氢可酮的前药KP201组成。该公司正在开发立即释放(IR)候选产品KP201/APAP,用于短期或不超过14天管理急性疼痛。该公司设计具备遏制滥用特性的KP201 /APAP,解决美国阿片滥用的流行病。该公司还专注于开发用于疼痛和注意缺陷障碍(ADHD)的其他前药候选产品。该公司产品包括KP201/IR(无APAP)、KP511/ER、KP415、KP606/IR和KP746。